Annals of Surgical Oncology

, Volume 26, Issue 11, pp 3727–3735 | Cite as

Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer

  • Keita Takahashi
  • Masayuki WatanabeEmail author
  • Ryotaro Kozuki
  • Tasuku Toihata
  • Akihiko Okamura
  • Yu Imamura
  • Shinji Mine
  • Naoki Ishizuka
Thoracic Oncology



Skeletal muscle loss during the early postoperative period frequently occurs during post-esophagectomy. Preoperative sarcopenia is a known prognostic factor. However, the prognostic significance of postoperative skeletal muscle loss remains unclear. This study was designed to clarify the impact of skeletal muscle loss during the early postoperative period on the prognosis of elderly patients undergoing esophagectomy.


We included 316 patients (age ≥ 65 years) who underwent esophagectomy. The skeletal muscle index (SMI) at the third lumber vertebra’s bottom level was measured using computed tomography (CT) before surgery and 4 months after surgery. The SMI reduction rate, patient’s prognosis, and recurrence rates were evaluated.


The SMI reduction rates in tertiles were < 1.25% in the first tertile (t1, n = 105), between 1.25 and 9.13% in the second tertile (t2, n = 106), and > 9.13% in the third tertile (t3, n = 105). Both relapse-free survival (RFS) and overall survival (OS) in t3 were significantly worse than those in t1 and t2 (p < 0.001). Therefore, we defined t3 as the massive reduction (MR) group and t1 and t2 as the limited reduction (LR) group. By univariate analysis, both RFS and OS were significantly poorer in the MR group than in LR. By multivariate analysis, the massive skeletal muscle loss during the early postoperative period was an independent factor for both RFS and OS.


Early postoperative skeletal muscle loss predicts both recurrence and poor survival.



The authors have nothing to disclose.

Supplementary material

10434_2019_7616_MOESM1_ESM.tif (620 kb)
Supplemental Fig. 1 Study population (TIFF 619 kb)
10434_2019_7616_MOESM2_ESM.tif (2.1 mb)
Supplemental Fig. 2 The method to assess skeletal muscle mass (green area); skeletal muscle index = skeletal muscle mass/height2 (cm2/m2) (TIFF 2186 kb)
10434_2019_7616_MOESM3_ESM.docx (70 kb)
Supplementary material 3 (DOCX 70 kb)


  1. 1.
    Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222(5):654–62.Google Scholar
  2. 2.
    Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260(2):259–66.CrossRefGoogle Scholar
  3. 3.
    Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8(6):545–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Baba Y, Yoshida N, Shigaki H, et al. Prognostic impact of postoperative complications in 502 patients with surgically resected esophageal squamous cell carcinoma: a retrospective single-institution study. Ann Surg. 2016;264(2):305–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Saeki H, Tsutsumi S, Tajiri H, et al. Prognostic significance of postoperative complications after curative resection for patients with esophageal squamous cell carcinoma. Ann Surg. 2017;265(3):527–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990s–1s.CrossRefPubMedGoogle Scholar
  7. 7.
    Ida S, Watanabe M, Yoshida N, et al. Sarcopenia is a predictor of postoperative respiratory complications in patients with esophageal cancer. Ann Surg Oncol. 2015;22(13):4432–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Nakashima Y, Saeki H, Nakanishi R, et al. Assessment of sarcopenia as a predictor of poor outcomes after esophagectomy in elderly patients with esophageal cancer. Ann Surg. 2018;267(6):1100–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Jarvinen T, Ilonen I, Kauppi J, Salo J, Rasanen J. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. World J Surg Oncol. 2018;16(1):27.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Reisinger KW, Bosmans JW, Uittenbogaart M, et al. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy predicts postoperative mortality in esophageal cancer surgery. Ann Surg Oncol. 2015;22(13):4445–52.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Elliott JA, Docherty NG, Eckhardt HG, et al. Weight loss, satiety, and the postprandial gut hormone response after esophagectomy: a prospective study. Ann Surg. 2017;266(1):82–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006.CrossRefPubMedGoogle Scholar
  13. 13.
    Yoshizumi T, Shirabe K, Nakagawara H, et al. Skeletal muscle area correlates with body surface area in healthy adults. Hepatol Res. 2014;44(3):313–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.CrossRefGoogle Scholar
  15. 15.
    Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22):5336–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg. 2007;94(12):1496–500.CrossRefPubMedGoogle Scholar
  18. 18.
    Harada K, Yoshida N, Baba Y, et al. Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus. 2018. Scholar
  19. 19.
    Park SY, Kim DJ, Suh JW, Byun GE. Risk factors for weight loss 1 year after esophagectomy and gastric pull-up for esophageal cancer. J Gastrointest Surg. 2018;22(7):1137–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Doki Y, Takachi K, Ishikawa O, et al. Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery. 2006;139(6):797–805.CrossRefPubMedGoogle Scholar
  21. 21.
    Miyazaki T, Tanaka N, Hirai H, et al. Ghrelin level and body weight loss after esophagectomy for esophageal cancer. J Surg Res. 2012;176(1):74–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu J, Xie X, Zhou C, Peng S, Rao D, Fu J. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardio-thoracic Surg. 2012;41(3):e7–11.CrossRefGoogle Scholar
  23. 23.
    Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Harimoto N, Shirabe K, Yamashita YI, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100(11):1523–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu J, Motoyama S, Sato Y, et al. Decreased skeletal muscle mass after neoadjuvant therapy correlates with poor prognosis in patients with esophageal cancer. Anticancer Res. 2016;36(12):6677–85.CrossRefPubMedGoogle Scholar
  26. 26.
    Huang DD, Ji YB, Zhou DL, et al. Effect of surgery-induced acute muscle wasting on postoperative outcomes and quality of life. J Surg Res. 2017;218:58–66.CrossRefPubMedGoogle Scholar
  27. 27.
    Takamori S, Toyokawa G, Okamoto T, et al. Clinical impact and risk factors for skeletal muscle loss after complete resection of early non-small cell lung cancer. Ann Surg Oncol. 2018;25(5):1229–36.CrossRefGoogle Scholar
  28. 28.
    Tsukioka T, Izumi N, Kyukwang C, et al. Loss of muscle mass is a novel predictor of postoperative early recurrence in N2-positive non-small-cell lung cancer. Ann Thorac Cardiovasc Surg. 2018;24(3):121–6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Miyake M, Morizawa Y, Hori S, et al. Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer. 2017;17(1):237.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fukushima H, Nakanishi Y, Kataoka M, Tobisu KI, Koga F. Postoperative changes in skeletal muscle mass predict survival of patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Clin Genitourinary Cancer. 2017;15(2):e229–38.CrossRefGoogle Scholar
  31. 31.
    Takeda Y, Akiyoshi T, Matsueda K, et al. Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy. PloS One. 2018;13(4):e0195406.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Mayanagi S, Tsubosa Y, Omae K, et al. Negative impact of skeletal muscle wasting after neoadjuvant chemotherapy followed by surgery on survival for patients with thoracic esophageal cancer. Ann Surg Oncol. 2017;24(12):3741–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    George J, Cannon T, Lai V, et al. Cancer cachexia syndrome in head and neck cancer patients: Part II. Pathophysiology. Head Neck. 2007;29(5):497–507.CrossRefPubMedGoogle Scholar
  34. 34.
    Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Ann Rev Nutr. 2006;26:435–61.CrossRefGoogle Scholar
  35. 35.
    Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS, Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Sci (New York, NY). 2000;289(5488):2363–6.CrossRefGoogle Scholar
  36. 36.
    Sorensen J. Lung cancer cachexia: can molecular understanding guide clinical management? Integrative Cancer Ther. 2018;17(3):1000–8.CrossRefGoogle Scholar
  37. 37.
    Rice TW, Ishwaran H, Hofstetter WL, et al. Esophageal cancer: associations with (pN+) lymph node metastases. Ann Surg. 2017;265(1):122–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Boshier PR, Ziff C, Adam ME, Fehervari M, Markar SR, Hanna GB. Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018. Scholar
  39. 39.
    Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–65.CrossRefPubMedGoogle Scholar
  40. 40.
    Tidball JG. Regulation of muscle growth and regeneration by the immune system. Nat Rev Immunol. 2017;17(3):165–78.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Froghi F, Sanders G, Berrisford R, et al. A randomised trial of post-discharge enteral feeding following surgical resection of an upper gastrointestinal malignancy. Clin Nutr (Edinburgh, Scotland). 2017;36(6):1516–9.CrossRefGoogle Scholar
  42. 42.
    Healy LA, Ryan A, Doyle SL, et al. Does prolonged enteral feeding with supplemental omega-3 fatty acids impact on recovery post-esophagectomy: results of a randomized double-blind trial. Ann Surg. 2017;266(5):720–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–31.CrossRefPubMedGoogle Scholar
  44. 44.
    Nakamura M, Nakamori M, Ojima T, et al. The effects of rikkunshito on body weight loss after esophagectomy. J Surg Res. 2016;204(1):130–8.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Keita Takahashi
    • 1
  • Masayuki Watanabe
    • 1
    Email author
  • Ryotaro Kozuki
    • 1
  • Tasuku Toihata
    • 1
  • Akihiko Okamura
    • 1
  • Yu Imamura
    • 1
  • Shinji Mine
    • 1
  • Naoki Ishizuka
    • 2
  1. 1.Department of Gastroenterological SurgeryThe Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan
  2. 2.Department of Clinical Trial Planning and ManagementThe Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations